Want to see ZLAB full AI Analyst Report?
Top Page
Zai Lab
(NASDAQ:ZLAB)
Select Model
Select Model
Rating:52Neutral
Price Target:
$24.50
▼(-8.65% Downside)
Action:Reiterated
Date:10/24/26
The score is held back primarily by weak financial performance (ongoing losses, negative free cash flow, and sharply negative TTM revenue growth). The latest earnings call adds support via sequential revenue improvement, strong cash, and a catalyst-rich pipeline, but technical indicators remain soft and valuation metrics provide limited support given negative earnings and no dividend.
Positive Factors
Commercial profitability and sequential growth
Sequential product growth alongside commercial profitability indicates that Zai Lab is converting its portfolio into a more productive operating base. If sustained, this combination can support reinvestment in launches and clinical programs while reducing dependence on external funding over time.
Negative Factors
Persistent operating losses
Zai Lab remains materially unprofitable at both operating and net-income levels, so portfolio growth has not yet translated into sustainable corporate earnings. Continued losses constrain internal funding capacity and make future profitability dependent on successful commercialization and disciplined expense management.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial profitability and sequential growth
Sequential product growth alongside commercial profitability indicates that Zai Lab is converting its portfolio into a more productive operating base. If sustained, this combination can support reinvestment in launches and clinical programs while reducing dependence on external funding over time.
Read all positive factors
Zai Lab (ZLAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.57B
Dividend YieldN/A
Average Volume (3M)840.30K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue Growth5.13%
EPS Growth17.00%
CountryUS
Employees1,784
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.76
Shares Outstanding113,782,810
10 Day Avg. Volume821,089
30 Day Avg. Volume840,302
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)2.70
Price to Sales (P/S)4.20
P/FCF Ratio-11.77
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue3.69
Enterprise Value/Gross Profit6.54
Enterprise Value/Ebitda-9.83
Forecast
1Y Price Target
$39.33Price Target Upside46.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-2.22
Revenue Forecast (FY)$421.64M
Zai Lab Business Overview & Revenue Model
Company Description
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmu...
How the Company Makes Money
Zai Lab generates revenue primarily from (1) product sales of commercial-stage medicines in its markets, where it records sales to distributors, hospitals, and other healthcare channels and earns gross profit after cost of goods sold; and (2) coll...
Zai Lab Earnings Call Summary
Earnings Call Date:Aug 06, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call emphasized multiple near-term and medium-term positive catalysts: sequential revenue growth (11% QoQ to $105.8M), a commercially profitable business, a strong cash balance ($717.5M), rapid advancement of Zoci into global registrational trials with notable efficacy signals (38.2% ORR vs ~18% comparator in neuroendocrine carcinoma), and a busy pipeline with several upcoming data milestones (ESMO presentation, ZL-1503 healthy volunteer data H2 2026, ZL-6201 initial data H1 2027, ZL-1311 IND by year-end). Management also highlighted disciplined spending and productivity efforts. Counterbalancing these positives are supply constraints, near-term revenue timing issues related to NRDL and formulation transitions, increasing competition in the IL-13/IL-31 AD space, clinical safety/combination risks, and some ambiguity around the timing of profitability and key readouts. Overall, the positives — particularly pipeline momentum, commercial profitability, and cash runway — outweigh the operational and timing uncertainties.Positive Updates
Sequential Revenue Growth and Commercial Profitability
Net product revenue grew 11% sequentially to $105.8 million in Q2 2026, and the company stated its commercial business remained commercially profitable.
Negative Updates
Supply Constraints and Near-Term Revenue Timing Issues
XACDURO is experiencing supply constraints. Management noted reported revenue in the second half of 2026 may not fully reflect underlying demand because of NRDL timing and the planned transition of VYVGART from IV to subcutaneous delivery.
Read all updates
Q2-2026 Updates
Positive
Negative
Sequential Revenue Growth and Commercial Profitability
Net product revenue grew 11% sequentially to $105.8 million in Q2 2026, and the company stated its commercial business remained commercially profitable.
Read all positive updates
Company Guidance
Management guided to both near‑term commercial stabilization and a fast, metric‑driven clinical cadence: commercially, Q2 net product revenue rose 11% sequentially to $105.8 million, the business remained commercially profitable, cash was $717.5 million at quarter‑end, operating expenses are expected to be broadly stable through the remainder of the year, they expect to stabilize product sales in H2 2026 and return to meaningful year‑over‑year growth in 2027 with a potential first U.S. product launch in 2028 (and targeted NRDL actions such as KarXT and VYVGART around 2027); clinically, they expect three registrational programs in SCLC and neuroendocrine carcinoma by year‑end 2026, Zoci’s global Phase III to complete enrollment in H1 2027 with a U.S. accelerated approval submission later in 2027 and approval anticipated in 2028, ~60 patients (median follow‑up ~8–9 months) to be presented at ESMO in October, dose exploration at 1.2 and 1.6 mg/kg with 1.6 mg/kg the planned RP2D, and a goal of materially improving on the current ~60–70% response/≈5‑month median PFS benchmark (targeting ~80% response and ~50% PFS improvement); immunology and earlier‑stage timelines include ZL‑1503 SAD/healthy‑volunteer PK/PD and ADA data in H2 2026 (biomarkers pSTAT6, TARC, CCL26), MAD AD data at a major conference next year, ZL‑6201 initial data in H1 2027, and an IND for ZL‑1311 by year‑end 2026, all underpinned by disciplined capital allocation and the claim that Zoci moved from IND to global pivotal in <2 years.Zai Lab Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 449.61M | 460.16M | 398.99M | 266.72M | 215.04M | 144.31M |
| Gross Profit | 253.90M | 269.07M | 251.13M | 170.90M | 141.02M | 92.07M |
| EBITDA | -168.80M | -158.25M | -242.99M | -365.11M | -434.84M | -689.46M |
| Net Income | -188.21M | -175.54M | -257.10M | -334.62M | -443.29M | -704.47M |
Balance Sheet | ||||||
| Total Assets | 1.07B | 1.17B | 1.19B | 1.04B | 1.22B | 1.61B |
| Cash, Cash Equivalents and Short-Term Investments | 617.52M | 689.57M | 779.67M | 806.45M | 1.01B | 1.41B |
| Total Debt | 254.58M | 224.26M | 153.47M | 15.15M | 20.39M | 15.54M |
| Total Liabilities | 467.76M | 456.88M | 344.86M | 240.18M | 174.54M | 230.00M |
| Stockholders Equity | 607.04M | 715.50M | 840.90M | 796.12M | 1.05B | 1.38B |
Cash Flow | ||||||
| Free Cash Flow | -162.52M | -164.21M | -276.39M | -206.67M | -392.63M | -568.18M |
| Operating Cash Flow | -133.38M | -150.79M | -214.87M | -198.18M | -367.64M | -549.23M |
| Investing Cash Flow | -39.05M | 307.87M | -375.19M | -10.78M | 420.02M | 249.96M |
| Financing Cash Flow | 44.64M | 72.35M | 349.89M | -6.43M | -1.73M | 820.20M |
Zai Lab Technical Analysis
Positive
26.82
Price Trends
25.23
Negative
22.28
Positive
20.87
Positive
Market Momentum
-0.43
Positive
48.37
Neutral
42.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZLAB, the sentiment is Positive. The current price of 26.82 is above the 20-day moving average (MA) of 24.52, above the 50-day MA of 25.23, and above the 200-day MA of 20.87, indicating a neutral trend. The MACD of -0.43 indicates Positive momentum. The RSI at 48.37 is Neutral, neither overbought nor oversold. The STOCH value of 42.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZLAB.
Zai Lab Risk Analysis
Zai Lab disclosed 101 risk factors in its most recent earnings report. Zai Lab reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zai Lab Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $6.38B | -19.30 | -40.51% | ― | 34.52% | 41.20% | |
57 Neutral | $2.77B | 10.10 | 49.34% | ― | 738.76% | ― | |
54 Neutral | $1.61B | -10.52 | -49.73% | ― | 1083.56% | 30.89% | |
52 Neutral | $2.57B | -13.01 | -27.40% | ― | 5.13% | 17.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $2.30B | -6.71 | -52.36% | ― | -97.27% | -44.90% | |
47 Neutral | $2.12B | -7.08 | -50.56% | ― | -100.00% | 18.12% |
* Healthcare Sector Average
ZLAB
Zai Lab
24.03
-2.29
-8.70%
CLDX
Celldex
29.25
2.53
9.47%
IOVA
Iovance Biotherapeutics
14.09
11.84
526.22%
NRIX
Nurix Therapeutics
25.34
14.25
128.49%
NUVB
Nuvation Bio
4.57
-0.28
-5.77%
IMNM
Immunome
17.99
2.30
14.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.